2 studies found for:    12697856 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Condition: Peritoneal Cancer
Interventions: Drug: Sorafenib;   Biological: Bevacizumab;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis;   Procedure: dynamic contract-enhanced magnetic resonance imaging;   Procedure: needle biopsy;   Procedure: positron emission tomography;   Radiation: fludeoxyglucose F 18
2 Completed BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
Condition: Neoplasms
Interventions: Drug: Bevacizumab;   Drug: BAY 43-9006

Indicates status has not been verified in more than two years